Enjoy complimentary customisation on priority with our Enterprise License!
The global Tourettes syndrome drugs market size is estimated to grow by USD 598.85 million at a CAGR of 6.69% between 2022 and 2027.
Technavio has segmented the market into product, distribution channel, and geography.
It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
The market share growth by the antipsychotic segment will be significant during the forecast period. Antipsychotic drugs held the largest share in the global Tourette's syndrome drugs market due to the ability of antipsychotic drugs to treat tics compared to non-antipsychotic drugs. These drugs are developed for treating schizophrenia and are hence they are known as antipsychotic drugs. Antipsychotic drugs mainly work by blocking dopamine in the brain, majorly in the D2 receptor.
Get a glance at the market contribution of various segments View a PDF Sample
The antipsychotic segment was valued at USD 695.33 million in 2017. Because some drugs are the most useful medications for minimizing tics dopamine is strongly connected with Tourette syndrome. Drugs such as Fluphenazine, Haloperidol (Haldol), pimozide (Orap), and risperidone (Risperdal) are the most used antipsychotic drugs for the treatment of Tourette syndrome. However, due to the growing reliability of end-users such as hospitals, healthcare providers, and clinics on antipsychotic drugs for the treatment of Tourette's syndrome, the antipsychotic segment of the global Tourette's syndrome drugs market is expected to rise during the forecast period.
Offline segment
The offline segment includes retail pharmacies and hospitals. Due to the increasing awareness and prevalence of the condition and breakthroughs in novel treatment options, the global Tourette's syndrome drugs market is predicted to grow significantly during the forecast period. Retail pharmacies are the most accessible and convenient source of medication because they provide a wide variety of drugs. The increasing prevalence of Tourette syndrome has raised the demand for medicines and other treatments. Hence, the offline segment is expected to drive the growth of the global
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America held the largest share of the global Tourette's syndrome drugs market owing to the factors such as the high incidences of Tourette syndrome, a highly aware population, favorable government initiatives such as reimbursements, and advanced healthcare infrastructure. Healthcare facilities in the US are having a positive impact on the growth of the market. Doe to the implementation of the Affordable Care Act in March 2010 has rapidly changed the business environment of the pharmaceutical industry in the US. This compels vendors and healthcare facilities to provide technologies and medical services at an affordable cost without compromising the clinical efficacy of drugs and therapeutics.
Moreover, in the US, government bodies are doing awareness campaigns for effectively managing Tourettes syndrome. For instance, the CDC plays an important role in integrating mental well-being with public health. Every year the CDC uses the Behavioral Risk Factor Surveillance System using a telephone-based questionnaire to track the health and risk behavior of people in the US. Besides, the HSR and D-initiated program Collaborative Care for Depression in the Primary Care Setting. Such campaigns increase the awareness of Tourette's syndrome among people, which will drive the growth of the regional Tourette syndrome drugs market during the forecast period.
The outbreak of COVID-19 in 2020 negatively affected the growth of the regional Tourettes syndrome drugs market. However, due to the initiation of large-scale COVID-19 vaccination drives by the government across the region in the second half of 2020 resulted in the resumption of operations in various facilities, including therapy centers. In addition, the adoption of online channels to procure medications for Tourette's syndrome, along with the resumption of activities in therapy centers and other related services, are contributing to the growth of the Tourettes syndrome drugs market in North America during the forecast period.
Buy Now Full Report and Discover More
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Eli Lilly and Co.: The company offers Tourette syndrome drugs which are used to treat symptoms of attention deficit hyperactivity disorder in children of ages six to twelve along with adults.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Increasing R&D investments for Tourette syndrome is the primary trend in the global Tourette's syndrome drugs market. The increase in R&D activities by pharmaceutical vendors such as AstraZeneca, Eli Lilly and Co., Johnson and Johnson, and Otsuka Holdings Co. Ltd. to develop new drugs for the treatment of Tourettes syndrome is a key factor that is driving the growth of the global Tourette's syndrome drugs market.
Moreover, For example, In November 2022, Emalex Biosciences Inc. raised Series D funds of approximately USD 250 million led by Bain Capital Life Sciences for the progress of the development of an investigational new drug for Tourette syndrome. Thus, the Increasing R&D investments by major players will drive the growth of the global Tourette's syndrome drugs market during the forecast period.
The social stigma associated with Tourette syndrome and the lack of awareness among people is the major challenge for the growth of the global Tourette's syndrome drugs market. Due to the lack of adequate knowledge about Tourette's syndrome, this is poorly understood in many parts of the world. Especially in low-income countries of Africa and South America because of the low literacy rates which can lead to ignorance about possible treatment options such as Tourette's syndrome drugs. Therefore, it is associated with stigmas, such as dejection, in most parts of the region. Most people do not know what to do about Tourettes syndrome even when they find it.
Furthermore, ignorance of Tourette syndrome results in early mature loss of self-dependence, reduced participation in social interactions, and low self-confidence. Stigmas related to Tourette syndrome not only affect the well-being of a person but also affect the volume consumption of the drugs used for the treatment. In addition, inaccurate assumptions may result in wrong interpretations about the impact of the disease. This can force caregivers to refrain from attending to their patients, which can exacerbate the condition of the patient. Hence, social stigmas associated with Tourette's syndrome patients require undergoing diagnosis, which results in reduces adoption of drugs and, Therefore, will become a challenge for the growth of the global Tourette's syndrome drugs market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Tourettes Syndrome Drugs Market Customer Landscape
The Tourettes syndrome drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Tourettes Syndrome Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
149 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.69% |
Market growth 2023-2027 |
USD 598.85 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.53 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 43% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Asarina Pharma AB, AstraZeneca, Bausch Health Co. Inc., Catalyst Pharmaceuticals Inc., Eli Lilly and Co., Emalex Biosciences Inc., H Lundbeck AS, Johnson and Johnson Services Inc., Medtronic Plc, Otsuka Holdings Co. Ltd., Paragon Biosciences LLC, Questex LLC, Reviva Pharmaceuticals Holdings Inc, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.